Femara (Letrozole) is a nonsteroidal aromatase inhibitor (AI) used to treat hormone receptor-positive breast cancer in postmenopausal women. In the body, it blocks the production of estrogen, a hormone that promotes the growth of certain types of breast tissue. It can be used by both men and woman for the above purposes of lower Aromatase enzyme present in the body. The secondary effect of this is lowering of conversion into estrgen and its metabolites dependant on testosterone and its derivatives present in the body.
Femara has a typical half-life of about 2-4 days and is usually taken once daily with or without food. The recommended dose for woman is 2.5 mg daily, but this may vary depending on the individual and specific health conditions. For men in lowering circulating estrogen and derivatives 0.5mg every other day should be sufficient. Dosage should vary according to once own sensitivity and should be gauged under the guidance of a medical practitioner.
Common side effects associated with Femara use include hot flashes, joint pain, nausea, fatigue, and headache. More serious side effects can include osteoporosis, liver problems, and an increased risk of heart disease. If you’re pregnant or breastfeeding or having a high bodyfat percentage you should consider using other drugs in place of Femara.
